A 34-year-old man with advanced HIV infection from the Bolivian Amazon presented initially with localized cutaneous leishmaniasis. After receiving pentavalent antimonial therapy without success, his condition evolved from a localized dermatosis to progressive dissemination. Clinically he developed numerous widespread ulcerated papules and nodules accompanied by systemic symptoms and marked weight loss.
The timeline and precise intervals between initial presentation, antimonial therapy, and progression were not reported in the abstract. The report identifies the setting as Bolivian Amazonia and frames the case as an example of a changing clinical spectrum of cutaneous leishmaniasis when coexisting with HIV infection.
Diagnostic work-up included microscopy of skin smears and histopathologic examination of lesional tissue. Both modalities demonstrated intracellular amastigotes, confirming leishmanial infection.
Species-level identification is not detailed in the abstract, but Leishmania amazonensis appears among the article keywords. Other laboratory or imaging data, immunologic parameters (for example CD4 count or viral load), and microbiological culture or molecular testing were not reported in the abstract.
Initial therapy with pentavalent antimonials failed to control the cutaneous disease. Following progression, the patient was treated sequentially with liposomal amphotericin B and, thereafter, oral miltefosine.
The combined regimen produced only a transitory clinical resolution; sustained remission was not achieved according to the abstract. Specific dosing, treatment durations, adverse events, and timing of responses were not provided in the abstract.
This case underlines several challenges clinicians face when managing cutaneous leishmaniasis in patients with HIV coinfection. Immunosuppression can modify the typical clinical presentation, facilitating dissemination and leading to atypical morphologies such as numerous ulcerated papules and nodules rather than isolated ulcers.
Diagnostic confirmation relied on demonstration of intracellular amastigotes by smear and histopathology in this patient. However, the authors note—by example—how the clinical classification of cutaneous leishmaniasis may be fluid in immunocompromised hosts, complicating clinical decision-making.
Therapeutically, standard agents may be less effective or produce only temporary improvement in the setting of HIV. In this case, pentavalent antimonials were ineffective, and a switch to liposomal amphotericin B followed by miltefosine resulted only in transient benefit. The abstract highlights the limited and unstable therapeutic responses that can occur with current antileishmanial treatments in coinfected and immunosuppressed patients.
The report therefore draws attention to the practical difficulties of achieving durable cure in coinfected patients and the need for vigilant follow-up, consideration of alternative or combined therapeutic strategies, and tailored management plans in endemic regions.
The authors emphasize the "changing spectrum" of cutaneous leishmaniasis presentations when occurring with HIV coinfection. In endemic settings such as the Bolivian Amazon, clinicians should maintain a high index of suspicion for leishmaniasis in people with HIV who present with atypical, disseminated, or treatment-refractory dermatologic lesions.
Key practical points from the case include:
This case report from Bolivian Amazonia documents an adult with advanced HIV infection whose localized cutaneous leishmaniasis became disseminated after failed antimonial therapy. Parasitologic confirmation was achieved via detection of intracellular amastigotes. Treatment with liposomal amphotericin B followed by oral miltefosine resulted only in transient clinical improvement. The authors use the case to illustrate diagnostic and therapeutic challenges and to stress that the clinical classification of cutaneous leishmaniasis may be dynamic in immunosuppressed hosts.
Details not provided in the abstract include exact treatment regimens and durations, species confirmation methods beyond the keywords, immunologic status metrics, and long-term outcomes. These elements would require consultation of the full text for further information.